TCGA-A8-A07S-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 8
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.360
- PROTEIN_SECRETION+0.330
- G2M_CHECKPOINT+0.260
- MYC_TARGETS_V1+0.250
- DNA_REPAIR+0.240
- NOTCH_SIGNALING+0.230
- E2F_TARGETS+0.220
- MITOTIC_SPINDLE+0.220
- ADIPOGENESIS+0.210
- INTERFERON_ALPHA_RESPONSE+0.180
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- INFLAMMATORY_RESPONSE-0.330
- TNFA_SIGNALING_VIA_NFKB-0.330
- CHOLESTEROL_HOMEOSTASIS-0.290
- IL6_JAK_STAT3_SIGNALING-0.240
- KRAS_SIGNALING_UP-0.240
- ANGIOGENESIS-0.230
- IL2_STAT5_SIGNALING-0.200
- INTERFERON_GAMMA_RESPONSE-0.180
- KRAS_SIGNALING_DN-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TJTEF70D | high-grade glioma | — | 0.834 |
| 2 | E3E4E7DA-AD14-44BA-B3BE-02652B3CEE18 | — | — | 0.830 |
| 3 | BS_FTKPQ5FZ | Supratentorial Ependymoma | — | 0.811 |
| 4 | MNG168 | — | — | 0.809 |
| 5 | BS_QXKRN6CR | EPN | Supratentorial EPN | 0.805 |
| 6 | TCGA-AR-A0U3-01A-11R-A109-07 | — | B | 0.794 |
| 7 | MDT-AP-1122 | Med | Medulloblastoma | 0.794 |
| 8 | BS_QXKRN6CR | Supratentorial Ependymoma | — | 0.791 |
| 9 | TCGA-A2-A0YG-01A-21R-A109-07 | — | C | 0.791 |
| 10 | MNG1213 | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |